Broad reactivity of HLA-E restricted TCRs highlights challenges in universal T cell therapy development 2335164

Résumé fourni par la source

Abstract Introduction T cell receptor—engineered therapies (TCR-Ts) redirect T cells to tumor antigens presented by human leukocyte antigen (HLA) molecules but are limited by the extreme polymorphism of classical HLAs, restricting broad applicability. HLA-E is a non-classical, functionally monomorphic HLA molecule that presents host- and virus-derived peptides and elicits CD8 T cell responses. Virus-associated malignancies disproportionately affect diverse populations, highlighting the need for broadly applicable immunotherapies. We investigated HLA-E—restricted TCRs as a platform for universal cellular therapy using a cytomegalovirus-derived epitope. Methods Peripheral blood mononuclear cells from CMV-seropositive donors were stimulated with antigen-presenting cells expressing HLA-E—VL9 (VMAPRTLLL). VL9-specific T cells were isolated by tetramer sorting and single-cell TCR sequencing. An HLA-E—null NFAT-luciferase reporter line expressing the VL9-TCR was used to assess activation against HLA-E—peptide complexes and cancer cell lines. Primary CD8 T cells underwent endogenous TCR and HLA-E knockout before VL9-TCR transduction. Results The VL9-TCR exhibited unexpected cross-reactivity to multiple HLA-E—bound peptides, corroborated by structural modeling. Reporter cells showed strong activation against HTLV-1+ and EBV+ leukemia and lymphoma lines, with moderate activation toward HPV+ cancers and healthy primary cells, indicating off-tumor activity. VL9-TCR—Ts demonstrated preferential HLA-E—dependent cytotoxicity against HTLV-1+ targets compared with healthy PBMCs. Conclusion HLA-E—VL9 TCR-Ts exhibit strong anti-tumor activity but also substantial peptide cross-reactivity, highlighting key safety challenges. Although the VL9-TCR itself is unlikely to be clinically viable, these results support HLA-E’s potential as a universal immunotherapy platform. Ongoing work focuses on identifying tumor-specific HLA-E—binding peptides and integrating synNotch logic-gated circuits to determine whether specificity can be enhanced. Funding Source American Society of Hematology, UNC Eshelman Innovation Topic Categories Transplantation Immunology (TRAN)

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.